Meeting
2022 ASCO Genitourinary Cancers Symposium
Use of bone modifying agents for metastatic castrate-resistant prostate cancer.
Authors
Aaron Philip Mitchell
Memorial Sloan Kettering Cancer Center, New York, NY
Aaron Philip Mitchell , Akriti Mishra Meza , Azeez Farooki , Katherine Panageas , Peter B. Bach , Allison Lipitz-Snyderman , Michael J. Morris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 55)
DOI
10.1200/JCO.2022.40.6_suppl.055
Abstract #
55
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Evaluation of treatment patterns and costs for patients with prostate cancer and bone metastases.
First Author: Adriana Valdarrama
Poster
2023 ASCO Quality Care Symposium
Cost to Medicare from bone modifying agent overuse in castration-sensitive prostate cancer.
First Author: Aaron Philip Mitchell
Poster
2018 Genitourinary Cancers Symposium
Patterns of progression in bone and soft tissue following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC).
First Author: Megan Ann McNamara
Poster
2017 ASCO Annual Meeting
Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Fatima Karzai